Navigation Links
Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing

NEW BRUNSWICK, N.J., July 7 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today announced that the Company recently closed on the remaining $3.0 million of its previously announced private placements with YA Global Investments, LP ("YA Global") and Stanford Venture Capital Holdings, Inc. ("Stanford"). Senesco has now received the entire amount of the milestone dependent $10 million private placements of secured convertible debentures and warrants.

Senesco primarily intends to utilize the proceeds of this financing to advance its research in multiple myeloma with the goal of filing an Investigational New Drug Application ("IND"). The Company estimates that it will take approximately 12 additional months from the date hereof to complete the steps necessary to file an IND, which steps include, but are not limited to, having the pharmaceutical grade materials manufactured and formulation and toxicology studies performed. Senesco believes that the proceeds from the combined $10 million private placements from YA Global and Stanford should be sufficient to allow it to complete these steps.

"Achieving the final funding milestones in less than one year further demonstrates the progress that we continue to make with our human health research program," said Bruce Galton, President and Chief Executive Officer of Senesco. "Closing on this last funding milestone allows Senesco to aggressively move forward in planning our toxicology studies and other activities necessary to prepare for our planned IND filing for our multiple myeloma product candidate."

The terms of the debentures and warrants were previously disclosed on a Form 8-K, dated August 1, 2007 and August 29, 2007 and in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The shares of common stock have been sold pursuant to an exemption from state and federal securities laws.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene- regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's ability to raise additional capital to fund its research and development efforts; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contact: Investor Relations Contact:

Senesco Technologies, Inc. FD

Joel Brooks Brian Ritchie

Chief Financial Officer (

( (212) 850-5600

(732) 296-8400

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
2. Senesco Technologies to Present at BIO 2008 Business Forum
3. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
4. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
5. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
6. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
7. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
8. Neurobiological Technologies CEO to Retire on December 31, 2008
9. M. D. Anderson Automates Laboratory Workflow with Stone Bond Technologies : EE-LIMS™ from Stone Bond Technologies Will Document Activities within the Laboratory Workflow at the siRNA Facility, Increasing Throughput, While Reducing Risks
10. BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008
11. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
Post Your Comments:
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
Breaking Biology Technology:
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):